SLC6A17 Knockout Cell Line (HCT 116)

The choice depends on whether you are studying SLC6A17's role as a brain-specific neutral amino acid transporter or its emerging functions in intellectual disability genetics. The Knockout line is appropriate for asking whether SLC6A17 is required for neutral amino acid transport in non-neuronal contexts. Note that SLC6A17 is predominantly expressed in brain (synaptic vesicles in glutamatergic neurons) — HCT 116 expresses minimal endogenous SLC6A17, making this model most useful for biochemical and inhibitor studies. For physiologically relevant SLC6A17 research — particularly intellectual disability modeling — neuronal cell systems are more appropriate. The EDITGENE Knockout in HCT 116 is useful for confirming complete loss in cells with low baseline expression, for heterologous expression studies, and for autosomal recessive intellectual disability disease variant rescue experiments in a controlled background.

Primary applications: • Heterologous expression studies: amino acid transport activity assessment using exogenous SLC6A17 in the clean knockout background. • Disease variant studies: rescue with autosomal recessive intellectual disability-associated SLC6A17 mutations for genotype-function correlation in a controlled context. • Substrate scope characterization: in vitro and cellular uptake of neutral amino acids to define SLC6A17 transport profile. • Subcellular localization studies: SLC6A17 is normally synaptic vesicular; imaging in heterologous expression characterizes targeting determinants. EDITGENE recommends this model for in vitro SLC6A17 biochemistry and disease variant studies. Neuronal contexts are more appropriate for physiological function studies.

Yes. SLC6A17 rescue experiments have specific considerations for a brain-specific transporter: • Construct design: use a codon-modified SLC6A17 sequence with a small C-terminal tag (FLAG, HA). The 12 transmembrane SLC6 architecture and SLC6A17's vesicular targeting signals must be preserved. • Heterologous expression context: HCT 116 is not the physiological cellular context for SLC6A17 — rescue is effectively a controlled heterologous expression study, useful for biochemical and disease variant characterization. • Disease mutation rescue: autosomal recessive intellectual disability-associated SLC6A17 variants enable genotype-function studies in a tractable cellular background. • Functional readout: rescue should restore neutral amino acid transport activity measured by uptake assays. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation. For physiological function studies, neuronal models are more appropriate.